Clinical Trials Directory

Trials / Completed

CompletedNCT02643147

Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
170 (actual)
Sponsor
Fundación para la Investigación del Hospital Clínico de Valencia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Worsening renal function (WRF) is a frequent finding in patients with decompensated acute heart failure (AHF) and it is associated to increased length of hospitalization and higher morbidity and mortality. Traditionally, WRF in AHF setting has been attributed to low cardiac output, but recent evidence also suggests venous congestion play a crucial role. Loop diuretics are the mainstay treatment of AHF, but their use traditionally has been associated to WRF, but also renal function improvement in patients with unequivocal signs of congestion. Nevertheless, traditional symptoms or signs of patients with AHF have shown a limited accuracy to neither identify nor quantify the degree of venous congestion. Recent authors have reported that plasma levels of antigen carbohydrate 125 (CA125) are closely related to the degree of venous congestion. The investigators hypothesize that CA125 may have a role for identifying the hyperhydrated (High CA125) patients that need high loop diuretic doses, and those with normal CA125 values needing low loop diuretic doses. In this randomized study (1:1) the investigators seek to evaluate whether a CA125 loop diuretic guided management therapy is superior to a standard strategy. The primary endpoint is the magnitude of changes of renal function at 24 and 72 hours after initiation of intravenous diuretic in an acute worsening of heart failure

Conditions

Interventions

TypeNameDescription
DRUGCA125 guided strategyInitial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
DRUGCA125 guided strategyInitial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
DRUGConventional StrategyThe dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations

Timeline

Start date
2015-01-01
Primary completion
2017-01-30
Completion
2017-01-30
First posted
2015-12-31
Last updated
2018-02-13

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT02643147. Inclusion in this directory is not an endorsement.